<DOC>
	<DOCNO>NCT00144534</DOCNO>
	<brief_summary>This open-label , extension , Phase III study evaluate long-term safety efficacy MRA patient RA participate Study MRA213JP .</brief_summary>
	<brief_title>Long-term Treatment Study MRA Rheumatoid Arthritis ( RA ) From Study MRA213JP</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion Either MRA placebo administer least 3 time precede study , confirm problem respect safety . In case Patients whose participation current study judge inappropriate problem precede study respect safety , Patients must methotrexate dose group precede study . Exclusion criterion Administered drug infliximab , etanercept , leflunomide within 12 week administration study drug Evaluated belonging Steinbrocker 's class IV within 4 week administration study drug Have register 3 month full codebreaking precede study Were administer plasma exchange therapy initiation precede study initial administration current study Treated surgically ( except local surgery ) within 4 week administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>